← Leaderboards
Russell William Jenkins
Massachusetts General Hospital
$2,741,448
Attributed
$2,741,448
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $631.1K · FY2018–25$1M$750K$500K$250K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,741,448 · 2
By mechanism
R37$1,795,798 · 1
K08$945,650 · 1
Top collaborators
No co-investigators on record.
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Jeffrey G Supko$3,480,570
- Jennifer A. Wargo$6,986,829
- Hensin Tsao$3,663,046
- David E Fisher$28,420,496
- Xiqun Chen$2,222,147
Others in their field
Other Emerging Leaders on “Pd-1 Blockade”
- Rachel Lena Rutishauser · University Of California, San Francisco$4,266,330
- Taha Merghoub · Sloan-Kettering Inst Can Research$4,017,014
- Jun Wang · New York University School Of Medicine$3,986,277
- J. Silvio Gutkind · University Of California, San Diego$3,818,732
- Andrew R Haas · University Of Pennsylvania$3,721,334
- Alexander Huang · University Of Pennsylvania$3,639,634
Research focus
Pd-1 BlockadeMyeloid CellsMalignant NeoplasmsResistanceSuccessCytokineImmune Checkpoint BlockadeLymphoid CellMouse ModelPd-1/Pd-L1ResponseBiological MarkersTumorTumor MicroenvironmentGenesImmuneImmunotherapyIn VivoMelanomaCd8-Positive T-LymphocytesTumor-Infiltrating Immune CellsPdl1 PathwayCombined Modality TherapyCombination Immunotherapy
Grant awards (8)
Dissecting the tumor-intrinsic and -extrinsic roles of TBK1 in tumor immunity$569,782
R37 · FY2025 · CA · contact PI
Dissecting the tumor-intrinsic and -extrinsic roles of TBK1 in tumor immunity$594,912
R37 · FY2024 · CA · contact PI
Dissecting the tumor-intrinsic and -extrinsic roles of TBK1 in tumor immunity$631,104
R37 · FY2023 · CA · contact PI
Ex Vivo Profiling of Immunotherapy Combinations Using Organotypic Tumor Spheroids$189,130
K08 · FY2022 · CA · contact PI
Ex Vivo Profiling of Immunotherapy Combinations Using Organotypic Tumor Spheroids$189,130
K08 · FY2021 · CA · contact PI
Ex Vivo Profiling of Immunotherapy Combinations Using Organotypic Tumor Spheroids$189,130
K08 · FY2020 · CA · contact PI
Ex Vivo Profiling of Immunotherapy Combinations Using Organotypic Tumor Spheroids$189,130
K08 · FY2019 · CA · contact PI
Ex Vivo Profiling of Immunotherapy Combinations Using Organotypic Tumor Spheroids$189,130
K08 · FY2018 · CA · contact PI